Search

Your search keyword '"Xiao-Yang Hu"' showing total 6 results
Start Over Author "Xiao-Yang Hu" Publisher bmc
6 results on '"Xiao-Yang Hu"'

1. Treating Acute EXacerbations of COPD with Chinese HerbAL MedIcine to aid AntiBiotic Use Reduction (EXCALIBUR): study protocol of a randomised double-blind, placebo-controlled feasibility trial

Author

Xiao-Yang Hu, Tom Oliver, Merlin Willcox, Catherine Simpson, Kerensa Thorne, Jeanne Trill, Nick Francis, Beth Stuart, Michael Thomas, Paul Little, Jian-Ping Liu, Gareth Griffiths, and Michael Moore

Subjects
Herbal medicine, Exacerbation, Chronic obstructive pulmonary disease, Randomised controlled trial, Feasibility, Qualitative, Medicine (General), R5-920
Abstract

Abstract Background Acute exacerbations of chronic obstructive pulmonary disease (AECOPD) are a major reason for consultations in primary care, hospital admissions, deterioration in function, and mortality. Despite the majority of exacerbations not being caused by bacteria, as many as 70% of patients who present in UK primary care with AECOPD are prescribed antibiotics as part of standard care. However, finding effective non-antibiotic treatments for COPD exacerbations is a priority to reduce antibiotic use. The Chinese herbal medicine Shufeng Jiedu® (SFJD) has the potential to reduce treatment failure and duration of hospital stay. This study aims to determine the feasibility of conducting a fully powered randomised, double blind, placebo-controlled clinical trial on SFJD for AECOPD in UK primary care. Methods This study is a phase III, two-arm individually double blind, randomised, placebo-controlled feasibility trial with nested qualitative study, coordinated by the Southampton Clinical Trial Unit (SCTU). Patients aged ≥ 40 years, with a current AECOPD, presenting with increased sputum purulence/volume, or breathlessness, and for whom the GP is considering use of antibiotics, will be eligible to participate. We aim to recruit seven eligible participants per month and randomise them to receive either the patent Chinese herbal medicine SFJD capsules or placebo for 14 consecutive days and to follow-up for 12 weeks. The primary outcomes include the feasibility of recruitment, study retention, and the percentage of diary completion. Discussion If this trial demonstrates the feasibility of recruitment, delivery, and follow-up, we will seek funding for a fully powered placebo-controlled trial of SFJD for the treatment of AECOPD in primary care. Trial registration This trial is registered via ISRCTN on 1 July 2021, identifier: ISRCTN26614726.

Published
2022
Full Text
View/download PDF

2. Effectiveness of digital interventions to improve household and community infection prevention and control behaviours and to reduce incidence of respiratory and/or gastro-intestinal infections: a rapid systematic review

Author

Natalie Gold, Xiao-Yang Hu, Sarah Denford, Ru-Yu Xia, Lauren Towler, Julia Groot, Rachel Gledhill, Merlin Willcox, Ben Ainsworth, Sascha Miller, Michael Moore, Paul Little, Richard Amlôt, Tim Chadborn, and Lucy Yardley

Subjects
Behaviour, Behaviour change, Behavioural medicine, Community health, COVID-19, Digital medicine, Public aspects of medicine, RA1-1270
Abstract

Abstract Background Digital interventions have potential to efficiently support improved hygiene practices to reduce transmission of COVID-19. Objective To evaluate the evidence for digital interventions to improve hygiene practices within the community. Methods We reviewed articles published between 01 January 2000 and 26 May 2019 that presented a controlled trial of a digital intervention to improve hygiene behaviours in the community. We searched MEDLINE, Embase, PsycINFO, Cochrane Controlled Register of Trials (CENTRAL), China National Knowledge Infrastructure and grey literature. Trials in hospitals were excluded, as were trials aiming at prevention of sexually transmitted infections; only target diseases with transmission mechanisms similar to COVID-19 (e.g. respiratory and gastrointestinal infections) were included. Trials had to evaluate a uniquely digital component of an intervention. Study designs were limited to randomised controlled trials, controlled before-and-after trials, and interrupted time series analyses. Outcomes could be either incidence of infections or change in hygiene behaviours. The Risk of Bias 2 tool was used to assess study quality. Results We found seven studies that met the inclusion criteria. Six studies reported successfully improving self-reported hygiene behaviour or health outcomes, but only one of these six trials, Germ Defence, confirmed improvements using objective measures (reduced consultations and antibiotic prescriptions). Settings included kindergartens, workplaces, and service station restrooms. Modes of delivery were diverse: WeChat, website, text messages, audio messages to mobiles, electronic billboards, and electronic personal care records. Four interventions targeted parents of young children with educational materials. Two targeted the general population; these also used behaviour change techniques or theory to inform the intervention. Only one trial had low risk of bias, Germ Defence; the most common concerns were lack of information about the randomisation, possible bias in reporting of behavioural outcomes, and lack of an analysis plan and possible selective reporting of results. Conclusion There was only one trial that was judged to be at low risk of bias, Germ Defence, which reduced incidence and severity of illness, as confirmed by objective measures. Further evaluation is required to determine the effectiveness of the other interventions reviewed. Trial registration PROSPERO CRD42020189919 .

Published
2021
Full Text
View/download PDF

3. Shufeng Jiedu capsules for treating acute exacerbations of chronic obstructive pulmonary disease: a systematic review and meta-analysis

Author

Ru-yu Xia, Xiao-yang Hu, Yu-tong Fei, Merlin Willcox, Ling-zi Wen, Ming-kun Yu, Li-shan Zhang, Meng-yuan Dai, Guang-he Fei, Mike Thomas, Nick Francis, Tom Wilkinson, Michael Moore, and Jian-ping Liu

Subjects
COPD, Exacerbation, Shufeng Jiedu, Systematic review, Meta-analysis, Chinese herbal medicine, Other systems of medicine, RZ201-999
Abstract

Abstract Background Chinese herbal medicine is widely used in combination with usual care for acute exacerbations of chronic obstructive pulmonary disease (AECOPD) in China. Chinese patent medicine Shufeng Jiedu (SFJD) capsules is widely used for respiratory infectious diseases. This review aims to evaluate effectiveness and safety of SFJD for AECOPD. Methods A systematic review of randomised controlled trials (RCTs) in patients with AECOPD, who received SFJD as a single intervention or as add-on treatment to usual care. PubMed, the Cochrane Library, EMBASE, Scopus, Web of Science and four Chinese databases were searched from inception to April 2019. Two authors screened trials, extracted data, and assessed risk of bias, independently. Meta-analysis was performed using RevMan 5.3 software. We performed subgroup analyses and sensitivity analyses according to the predefined protocol. Quality of evidence was assessed using GRADE. Results Thirteen RCTs (1036 patients, with 936 inpatients) were included, all compared SFJD in combination with usual care (including antibiotics) to usual care alone. The mean age of participants ranged from 52 to 67 years, with approximately 60% male. Due to lack of blinding and other factors, all trials were of high risk of bias. SFJD was associated with a significant reduction in treatment failure, from 20.1 to 8.3% (11 trials; 815 patients; relative risk 0.43, 95% confidence interval [CI] 0.30 to 0.62), and duration of hospital stay (2 trials; 79 patients; mean difference − 4.32 days, 95% CI − 5.89 to − 2.75 days). No significant difference in adverse events was found between SFJD and control groups. Conclusion Low certainty evidence suggests SFJD may bring additional benefit in reducing treatment failure, shorten hospital stay, and improving symptoms. Further large, high quality RCTs are needed to confirm its benefit and safety. Trial registration PROSPERO CRD42019133682 .

Published
2020
Full Text
View/download PDF

4. World Congress Integrative Medicine & Health 2017: Part one

Author

Benno Brinkhaus, Torkel Falkenberg, Aviad Haramati, Stefan N. Willich, Josephine P. Briggs, Merlin Willcox, Klaus Linde, Töres Theorell, Lisa M. Wong, Jeffrey Dusek, Darong Wu, David Eisenberg, Bettina Berger, Kathi Kemper, Beate Stock-Schröer, Hedda Sützl-Klein, Rosaria Ferreri, Gary Kaplan, Harald Matthes, Gabriele Rotter, Elad Schiff, Zahi Arnon, Eckhard Hahn, Christina M. Luberto, David Martin, Silke Schwarz, Diethard Tauschel, Andrew Flower, Harsha Gramminger, Hedwig H. Gupta, S. N. Gupta, Annette Kerckhoff, Christian S. Kessler, Andreas Michalsen, Eun S. Kim, Eun H. Jang, Rana Kim, Sae B. Jan, Martin Mittwede, Wiebke Mohme, Eran Ben-Arye, Massimo Bonucci, Bashar Saad, Thomas Breitkreuz, Elio Rossi, Rejin Kebudi, Michel Daher, Samaher Razaq, Nahla Gafer, Omar Nimri, Mohamed Hablas, Gunver Sophia Kienle, Noah Samuels, Michael Silbermann, Lena Bandelin, Anna-Lena Lang, Eva Wartner, Christoph Holtermann, Maxwell Binstock, Robert Riebau, Edin Mujkanovic, Holger Cramer, Romy Lauche, Andres Michalsen, Lesley Ward, Dominik Irnich, Wolfram Stör, Geoffrey Burnstock, Hans-Georg Schaible, Thomas Ots, Jost Langhorst, Tobias Sundberg, Catherina Amarell, Melanie Anheyer, Marion Eckert, Mercedes Ogal, Annette Schönauer, Birgit Reisenberger, Bernhard Brand, Dennis Anheyer, Gustav Dobos, Matthias Kroez, Aldo Ammendola, Jun J. Mao, Claudia Witt, Yufei Yang, Miriam Oritz, Markus Horneber, Petra Voiß, Alexandra von Rosenstiel, Catharina Amarell, Friedemann Schad, Marc Schläppi, Matthias Kröz, Arndt Büssing, Gil Bar-Sela, David Avshalomov, Samuel Attias, Sian Cotton, Miek Jong, Mats Jong, Christian Scheffer, Friedrich Edelhäuser, Abdullah AlBedah, Myeong Soo Lee, Mohamed Khalil, Keiko Ogawa, Yoshiharu Motoo, Junsuke Arimitsu, Masao Ogawa, Genki Shimizu, Rainer Stange, Karin Kraft, Kenny Kuchta, Kenji Watanabe, D Bonin, Harald Gruber, Sabine Koch, Urs Pohlmann, Christine Caldwell, Barbara Krantz, Ria Kortum, Lily Martin, Lisa S. Wieland, Ben Kligler, Susan Gould-Fogerite, Yuqing Zhang, John J. Riva, Michael Lumpkin, Emily Ratner, Liu Ping, Pei Jian, Gesa-Meyer Hamme, Xiaosong Mao, Han Chouping, Sven Schröder, Josef Hummelsberger, Michael Wullinger, Marc Brodzky, Christoff Zalpour, Julia Langley, Wendy Weber, Lanay M. Mudd, Peter Wayne, Clauda Witt, Wolfgang Weidenhammer, Vinjar Fønnebø, Heather Boon, Amie Steel, Andrea Bugarcic, Melisa Rangitakatu, Jon Adams, David Sibbritt, Jon Wardle, Matthew Leach, Janet Schloss, Helene Dieze, Nadine Ijaz, Michael Heinrich, George Lewith, Bertrand Graz, Daniela Adam, Linus Grabenhenrich, Miriam Ortiz, Sylvia Binting, Thomas Reinhold, Susanne Andermo, Johanna Hök Nordberg, Maria Arman, Manoj Bhasin, Xueyi Fan, Towia Libermann, Gregory Fricchione, John Denninger, Herbert Benson, David D. Martin, Inge Boers, Arine Vlieger, Michael Teut, Alexander Ullmann, Fabian Lotz, Stephanie Roll, Claudia Canella, Michael Mikolasek, Matthias Rostock, Jörg Beyer, Matthias Guckenberger, Josef Jenewein, Esther Linka, Claudia Six, Sarah Stoll, Roger Stupp, Claudia M. Witt, Elisabeth Chuang, Melissa D. McKee, Petra Klose, Silke Lange, Vincent C. H. Chung, Hoi L. C. Wong, Xin Y. Wu, Grace Y. G. Wen, Robin S. T. Ho, Jessica Y. L. Ching, Justin C. Y. Wu, Amanda Coakley, Jane Flanagan, Christine Annese, Joanne Empoliti, Zishan Gao, Xugang Liu, Shuguang Yu, Xianzhong Yan, Fanrong Liang, Christoph D. Hohmann, Nico Steckhan, Thomas Ostermann, Arion Paetow, Evelyn Hoff, Xiao-Yang Hu, Ruo-Han Wu, Martin Logue, Clara Blonde, Lily Y. Lai, Beth Stuart, Yu-Tong Fei, Michael Moore, Jian-Ping Liu, Michael Jeitler, Hannah Zillgen, Manuel Högl, Barbara Stöckigt, Georg Seifert, Christian Kessler, Talat Khadivzadeh, Maryam Hassanzadeh Bashtian, Shapour Badiee Aval, Habibollah Esmaily, Jihye Kim, Keun H. Kim, Carina Klocke, Stefanie Joos, Abdulrahman Koshak, Li Wie, Emad Koshak, Siraj Wali, Omer Alamoudi, Abdulrahman Demerdash, Majdy Qutub, Peter Pushparaj, Sigrid Kruse, Isabell Fischer, Nadine Tremel, Joseph Rosenecker, Brenda Leung, Wendy Takeda, Ning Liang, Xue Feng, Jian-ping Liu, Hui-juan Cao, Nina Shinday, Lisa Philpotts, Elyse Park, Gregory L. Fricchione, Gloria Yeh, Niki Munk, Arash Zakeresfahani, Trevor R. Foote, Rick Ralston, Karen Boulanger, Dominik Özbe, Elmar Gräßel, Katharina Luttenberger, Anna Pendergrass, Daniel Pach, Judit Bellmann-Strobl, Yinhui Chang, Laura Pasura, Bin Liu, Sven F. Jäger, Ronny Loerch, Li Jin, Katja Icke, Xuemin Shi, Friedemann Paul, Michaela Rütz, Andreas Lynen, Meike Schömitz, Maik Vahle, Nir Salomon, Alon Lang, Adi Lahat, Uri Kopylov, Shomron Ben-Horin, Ofir Har-Noi, Benjamin Avidan, Rami Elyakim, Dorit Gamus, Siew NG, Jessica Chang, Justin Wu, John Kaimiklotis, Dania Schumann, Ludovica Buttó, Dirk Haller, Caroline Smith, Sheryl de Lacey, Michael Chapman, Julie Ratcliffe, Neil Johnson, Jane Lyttleton, Clare Boothroyd, Paul Fahey, Bram Tjaden, Marja van Vliet, Herman van Wietmarschen, Wilfried Tröger, Pia Vuolanto, Paulina Aarva, Minna Sorsa, Kaija Helin, Claudia Wenzel, Iris Zoderer, Patricia Pammer, Patrick Simon, Gerhard Tucek, Kathrin Wode, Roger Henriksson, Lena Sharp, Anna Stoltenberg, Yang Xiao-ying, Li-qiong Wang, Jin-gen Li, Ying Wang, Lynda Balneaves, Rielle Capler, Chiara Bocci, Marta Guffi, Marina Paolini, Ilaria Meaglia, Patrizia Porcu, Giovanni B. Ivaldi, Simona Dragan, Petru Bucuras, Ana M. Pah, Marius Badalica-Petrescu, Florina Buleu, Gheorghe Hogea-Stoichescu, Ruxandra Christodorescu, Lan Kao, Yumin Cho, Nadja Klafke, Cornelia Mahler, Cornelia von Hagens, Lorenz Uhlmann, Martina Bentner, Andreas Schneeweiss, Andreas Mueller, Joachim Szecsenyi, Isabella Neri, Katharina Schnabel, Margit Cree, Ralf Suhr, Sonia Baccetti, Fabio Firenzuoli, Maria V. Monechi, Mariella Di Stefano, Gianni Amunni, Wendy Wong, Bingzhong Chen, Hakima Amri, Lucy Kotlyanskaya, Belinda Anderson, Roni Evans, Paul Marantz, Ryan Bradley, Cathryn Booth-LaForce, Heather Zwickey, Benjamin Kligler, Audrey Brooks, Mary J. Kreitzer, Patricia Lebensohn, Elisabeth Goldblatt, Neus Esmel-Esmel, Maria Jiménez-Herrera, Alexandra Jocham, Pascal O. Berberat, Antonius Schneider, Morgana Masetti, Henriette Murakozy, Marja Van Vliet, Rita Agdal, Fatemeh Atarzadeh, Amir M. Jaladat, Leila Hoseini, Fatemeh Amini, Chen Bai, Tiegang Liu, Zian Zheng, Yuxiang Wan, Jingnan Xu, Xuan Wang, He Yu, Xiaohong Gu, Babak Daneshfard, Majid Nimrouzi, Vahid Tafazoli, Seyed M. Emami Alorizi, Seyed A. Saghebi, Mohammad R. Fattahi, Alireza Salehi, Hossein Rezaeizadeh, Mohammad M. Zarshenas, Kealoha Fox, John Hughes, Nenad Kostanjsek, Stéphane Espinosa, Peter Fisher, Abdul Latif, Donald Lefeber, William Paske, Ali Ö. Öztürk, Gizemnur Öztürk, Wim Tissing, Marianne Naafs, Martine Busch, Mohammad R. Sanaye, Kilian Dräger, Brent Leininger, Kate Shafto, Jenny Breen, Ana P. Simões-Wüst, Carolina Moltó-Puigmartí, Martien van Dongen, Pieter Dagnelie, Carel Thijs, Shelley White, Solveig Wiesener, Anita Salamonsen, Trine Stub, Sergio Abanades, Mar Blanco, Laia Masllorens, Roser Sala, Shafekah Al-Ahnoumy, Dongwoon Han, Luzhu He, Ha Yun Kim, Da In Choi, Terje Alræk, Agnete Kristoffersen, Christel von Sceidt, Stig Bruset, Frauke Musial, Felix J. Saha, Heidemarie Haller, Hoda Azizi, Nayereh Khadem, Malihe Hassanzadeh, Nazanin Estiri, Hamideh Azizi, Fatemeh Tavassoli, Marzieh Lotfalizadeh, Reza Zabihi, Mahmoud Mohammadzadeh Shabestari, Reza Paeizi, Masoumeh Alvandi Azari, Hamidreza Bahrami-Taghanaki, Erik Baars, Anja De Bruin, Anne Ponstein, Sergio Segantini, Maria Valeria Monechi, Fabio Voller, Jürgen Barth, Alexandra Kern, Sebastian Lüthi, Anja Zieger, Fabius Otto, Ariel Beccia, Corina Dunlap, Brendan Courneene, Paula Bedregal, Alvaro Passi, Alfredo Rodríguez, Mayling Chang, Soledad Gutiérrez, Florian Beissner, Christine Preibisch, Annemarie Schweizer-Arau, Roxana Popovici, Karin Meissner, Sylvie Beljanski, Laura Belland, Laura Rivera-Reyes, Ula Hwang, Dominik Sethe, Dörte Hilgard, Peter Heusser, Felicity Bishop, Miznah Al-Abbadey, Katherine Bradbury, Dawn Carnes, Borislav Dimitrov, Carol Fawkes, Jo Foster, Hugh MacPherson, Lisa Roberts, Lucy Yardley, Michelle Holmes, Paul Little, Cyrus Cooper, Patrizia Bogani, Valentina Maggini, Eugenia Gallo, Elisangela Miceli, Sauro Biffi, Alessio Mengoni, Renato Fani, Nadine Brands-Guendling, Peter W. Guendling, Gert Bronfort, Mitch Haas, Craig Schulz, Xiangwei Bu, J. Wang, T. Fang, Z. Shen, Y. He, X. Zhang, Zhengju Zhang, Dali Wang, Fengxian Meng, Klaus Baumann, Eckhard Frick, Christoph Jacobs, Ralph-Achim Grünther, Désirée Lötzke, Sonny Jung, Daniela R. Recchia, Sibylle Robens, Josephin Stankewitz, Mika Jeitler, Chunhoo Cheon, Bo H. Jang, Seong G. Ko, Ching W. Huang, Yui Sasaki, Youme Ko, Anna Cheshire, Damien Ridge, David Peters, Maria Panagioti, Chantal Simon, Hyun J. Cho, Soo J. Choi, Young S. Jung, Hyea B Im, Kieran Cooley, Laura Tummon-Simmons, Rachel Wasson, Kristen Kraemer, Richard Sears, Carly Hueber, Gwendolyn Derk, JR Lill, Ruopeng An, Lois Steinberg, Lourdes Diaz Rodriguez, Francisca García-de la Fuente, Miguel De la Vega, Keyla Vargas-Román, Jonatan Fernández-Ruiz, Irene Cantarero-Villanueva, Francisca García-De la Fuente, Fanny Jiménez-Guerrero, Noelia Galiano-Castillo, Gualberto Diaz-Saez, José I. Torres-Jimenez, Olga Garcia-Gomez, Luis Hortal-Muñoz, Camino Diaz-Diez, Demijon Dicen, Helene Diezel, Jane Frawley, Alex Broom, Fei Dong, Xueyan Ma, Liyi Yan, Liqun Wu, Jiaju Ma, Jianhua Zhen, Julie Dubois, Pierre-Yves Rodondi, Sophia Schwartze, Barbara Trapp, and Dirk Cysarz

Subjects
Other systems of medicine, RZ201-999
Published
2017
Full Text
View/download PDF

5. Shufeng Jiedu capsules for treating acute exacerbations of chronic obstructive pulmonary disease: a systematic review and meta-analysis

Author

Yutong Fei, Meng-yuan Dai, Merlin Willcox, Lingzi Wen, Mingkun Yu, Nick A Francis, Tom Wilkinson, Michael Moore, Jianping Liu, Mike Thomas, Xiao-Yang Hu, Guanghe Fei, Li-shan Zhang, and Ruyu Xia

Subjects
medicine.medical_specialty, Blinding, Chinese patent medicine, Exacerbation, Capsules, Cochrane Library, law.invention, 03 medical and health sciences, Pulmonary Disease, Chronic Obstructive, 0302 clinical medicine, Randomized controlled trial, law, Internal medicine, medicine, Humans, COPD, 030212 general & internal medicine, Adverse effect, Randomized Controlled Trials as Topic, Randomised controlled trial, business.industry, Shufeng Jiedu, lcsh:Other systems of medicine, lcsh:RZ201-999, Meta-analysis, 030228 respiratory system, Complementary and alternative medicine, Relative risk, Systematic review, Chinese herbal medicine, business, Drugs, Chinese Herbal, Research Article
Abstract

Background Chinese herbal medicine is widely used in combination with usual care for acute exacerbations of chronic obstructive pulmonary disease (AECOPD) in China. Chinese patent medicine Shufeng Jiedu (SFJD) capsules is widely used for respiratory infectious diseases. This review aims to evaluate effectiveness and safety of SFJD for AECOPD. Methods A systematic review of randomised controlled trials (RCTs) in patients with AECOPD, who received SFJD as a single intervention or as add-on treatment to usual care. PubMed, the Cochrane Library, EMBASE, Scopus, Web of Science and four Chinese databases were searched from inception to April 2019. Two authors screened trials, extracted data, and assessed risk of bias, independently. Meta-analysis was performed using RevMan 5.3 software. We performed subgroup analyses and sensitivity analyses according to the predefined protocol. Quality of evidence was assessed using GRADE. Results Thirteen RCTs (1036 patients, with 936 inpatients) were included, all compared SFJD in combination with usual care (including antibiotics) to usual care alone. The mean age of participants ranged from 52 to 67 years, with approximately 60% male. Due to lack of blinding and other factors, all trials were of high risk of bias. SFJD was associated with a significant reduction in treatment failure, from 20.1 to 8.3% (11 trials; 815 patients; relative risk 0.43, 95% confidence interval [CI] 0.30 to 0.62), and duration of hospital stay (2 trials; 79 patients; mean difference − 4.32 days, 95% CI − 5.89 to − 2.75 days). No significant difference in adverse events was found between SFJD and control groups. Conclusion Low certainty evidence suggests SFJD may bring additional benefit in reducing treatment failure, shorten hospital stay, and improving symptoms. Further large, high quality RCTs are needed to confirm its benefit and safety. Trial registration PROSPERO CRD42019133682.

Published
2020

6. Association between admission hypothermia and outcomes in very low birth weight infants in China: a multicentre prospective study

Author

Yong-hui Yu, Li Wang, Lei Huang, Li-ling Wang, Xiao-yang Huang, Xiu-fang Fan, Yan-jie Ding, Cheng-yuan Zhang, Qiang Liu, Ai-rong Sun, Yue-hua Zhao, Guo Yao, Cong Li, Xiu-xiang Liu, Jing-cai Wu, Zhen-ying Yang, Tong Chen, Xue-yun Ren, Jing Li, Mei-rong Bi, Fu-dong Peng, Min Geng, Bing-ping Qiu, Ri-ming Zhao, Shi-ping Niu, Ren-xia Zhu, Yao Chen, Yan-ling Gao, and Li-ping Deng

Subjects
Very low birth weight infants, Extremely low birth weight infants, Admission hypothermia, Outcome, Pediatrics, RJ1-570
Abstract

Abstract Background The objective of this prospective, multicentre, observational cohort study was to evaluate the association between admission hypothermia and neonatal outcomes in very low-birth weight (VLBW) infants in multiple neonatal intensive care units (NICUs) in China. Methods Since January 1, 2018, a neonatal homogeneous cooperative research platform-Shandong Neonatal Network (SNN) has been established. The platform collects clinical data in a prospective manner on preterm infants with birth weights (BWs)

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results